Short-Term Therapy with Rosiglitazone, a PPAR-𝜸 Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats

Table 1

Physiological and metabolic characteristics of the 2 experimental groups. Data are mean ± SEM.

	Controls	Rosiglitazone
	(𝑛=10)
Body weight (g)
(i) Initial	300.2±5.4	302.7±4.9
(ii) Final	325.5±5.6	339.9±8.7
Gonadal fat-pad mass (g)	1.13±0.06	1.47±0.09^a
Perirenal fat-pad mass (g)	1.12±0.08	1.31±0.12
Gastrocnemius muscle mass (g)	1.86±0.05	1.92±0.06
Fat/lean ratio^*	1.23±0.07	1.45±0.08
Plasma triglycerides (mM)	1.34±0.11	0.50±0.04^b
Plasma NEFA (mM)	0.20±0.01	0.08±0.00^b
Total cholesterol	2.33±0.10	2.40±0.96
HDL cholesterol	0.92±0.08	1.01±0.08
LDL cholesterol	2.12±0.20	2.66±0.17
Hematocrit	45.9±0.2	41.8±0.5^b

^*Fat/Lean ratio = sum of white fat pad masses/gastrocnemius muscle mass; ^a𝑃<0.01, ^b𝑃<0.001 versus controls.